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PLATELETS AND THROMBOPOIESIS
Evaluation of participants with suspected heritable platelet function disorders
including recommendation and validation of a streamlined agonist panel
Ban B. Dawood,1 Gillian C. Lowe,1 Marie Lordkipanidze´,1 Danai Bem,1 Martina E. Daly,2 Mike Makris,2 Andrew Mumford,3
Jonathan T. Wilde,4 and Steve P. Watson1
1Department of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; 2Department of
Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom; 3Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol, United
Kingdom; and 4Adult Haemophilia Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom
Light transmission aggregometry (LTA) is
used worldwide for the investigation of
heritable platelet function disorders
(PFDs), but interpretation of results is
complicated by the feedback effects of
ADP and thromboxane A2 (TxA2) and by
the overlap with the response of healthy
volunteers. Over 5 years, we have per-
formed lumi-aggregometry on 9 platelet
agonists in 111 unrelated research partici-
pants with suspected PFDs and in
70 healthy volunteers. Abnormal LTA or
ATP secretion test results were identified
in 58% of participants. In 84% of these,
the patterns of response were consistent
with defects in Gi receptor signaling, the
TxA2 pathway, and dense granule secre-
tion. Participants with defects in signal-
ing to Gq-coupled receptor agonists and
to collagen were also identified. Targeted
genotyping identified 3 participants with
function-disrupting mutations in the P2Y12
ADP and TxA2 receptors. The results of
the present study illustrate that detailed
phenotypic analysis using LTA and ATP
secretion is a powerful tool for the diagno-
sis of PFDs. Our data also enable subdivi-
sion at the level of platelet-signaling path-
ways and in some cases to individual
receptors. We further demonstrate that
most PFDs can be reliably diagnosed
using a streamlined panel of key platelet
agonists and specified concentrations
suitable for testing in most clinical diag-
nostic laboratories. (Blood. 2012;120(25):
5041-5049)
Introduction
An adequate number of normally functioning platelets is essential
in arresting hemorrhage from an injured blood vessel. Subjects
with heritable platelet function disorders (PFDs) experience life-
long abnormal bleeding, typically at mucocutaneous sites or
elsewhere after trauma or invasive procedures. This group of
disorders is highly heterogeneous and can arise through defects in
surface membrane receptors, signaling pathways, granule forma-
tion and secretion, cytoskeletal remodeling, and expression of
procoagulant activity.1,2 Diagnosis of the severe PFDs, such as
Glanzmann thrombasthenia and Bernhard-Soulier syndrome, or
syndromic PFDs, such as Hermansky Pudlak syndrome, is usually
straightforward because of the characteristic clinical and laboratory
features.3-6 Conversely, poor standardization of platelet function
tests and the lack of consensus surrounding minimal diagnostic
criteria have hampered diagnosis of the remaining PFDs.
Light transmission aggregometry (LTA) is a long-established
method for the diagnosis of PFDs. Responses to individual test
agonists are typically classified as “abnormal” if numerical param-
eters such as the level of maximal aggregation fall outside of the
reference range of healthy donor controls or if there are qualitative
differences between test and control aggregation curves.7,8 How-
ever, most PFDs are associated with “abnormal responses” to
multiple agonists and it is unclear whether it is the number of
abnormal responses8 or the specific patterns of abnormal re-
sponses9 that is more powerful in the diagnosis of PFDs. The
additional diagnostic value of ATP secretion in the diagnosis of
PFDs is not known.
We have previously defined reference intervals for LTA and
dense granule secretion to 3 concentrations of 9 platelet agonists in
a cohort of 20 healthy volunteers.9 We now present data from the
United Kingdom Genotyping and Phenotyping of Platelets (GAPP)
study,10 which includes extended data on 70 healthy donor controls
that validate our previous reference intervals.9 We also describe
LTA and ATP secretion test results in a prospectively studied cohort
of 111 patients with suspected PFDs registered at United Kingdom
Hemophilia Comprehensive Care Centres. Detailed analysis of
LTA and ATP secretion using several concentrations of the ex-
tended panel of 9 agonists confirmed PFDs in approximately
60% of participants. More than 80% of this group exhibited defects
in Gi receptor signaling, the thromboxane A2 (TxA2) pathway, or
dense granule secretion. Further, a retrospective blinded analysis
revealed that approximately 90% of PFDs can be identified with a
restricted range of concentrations of 6 platelet agonists, which we
term a “streamlined agonist panel.” This indicates that reliable
diagnosis of PFDs and definition of the major pathways is feasible
in nonspecialist clinical diagnostic laboratories using a combina-
tion of LTA and ATP secretion.
Methods
Selection of participants
Participants with bleeding symptoms. Participants with suspected platelet
function defects were referred from August 2006 to September 2011 from
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United Kingdom Comprehensive Care Hemophilia Centres and were
invited to participate in this study if they satisfied all of the following
inclusion criteria: (1) abnormal bleeding symptoms compatible with PFD
(spontaneous mucocutaneous bleeding or abnormal bleeding at other sites
following trauma or invasive procedures); (2) results from coagulation
factor tests all within local laboratory reference intervals (minimum panel
of prothrombin time, activated thromboplastin time, Clauss fibrinogen
activity, VWF ristocetin cofactor activity, and activities of factors VIII,
IX and XI; and (3) absence of demonstrable for acquired platelet dysfunc-
tion. Patients with existing diagnoses of Glanzmann thrombasthenia,
Bernard-Soulier syndrome, or Hermansky-Pudlak syndrome and those with
platelet counts  100 or  450  109/L were excluded. Laboratory testing
was deferred in participants exposed within 2 weeks to drugs known to
affect platelet function. Information on the age and sex of the participants is
given in the “Results.”
Healthy controls. Healthy donor volunteers 18 years of age or older
were also included in this study. Controls were considered healthy if they
did not have a history of bleeding symptoms, did not require long-term
medical therapy, and had refrained from drugs known to influence platelet
function in the previous 2 weeks.
Ethics. This study was approved by the National Research Ethics
Service Committee West Midlands–Edgbaston (REC reference: 06/MRE07/
36), and participants and controls gave written informed consent in
accordance with the Declaration of Helsinki.
Platelet agonists and other reagents
ADP, adrenaline, and U46619 were purchased from Sigma-Aldrich.
Arachidonic acid (sodium salt) was from Cayman Chemical. Horm
collagen was from Nycomed Austria. The PAR-1 receptor–specific peptide
SFLLRN was from Alta Bioscience Laboratory (University of Birming-
ham, Birmingham, United Kingdom), and the PAR-4 receptor–specific
peptide AYPGKF and collagen-related peptide (CRP) were from Dr
Richard Farndale (Cambridge University, Cambridge, United Kingdom).
Luciferin-luciferase reagent (Chrono-Lume) was from the Chrono-log
Corporation. AR-C67085 was a gift from AstraZeneca. Rhodocytin was a
gift from Dr Johannes Eble (Frankfurt University Hospital, Frankfurt,
Germany).
Platelet preparation and measurement of aggregation
and secretion
Blood from participants and a simultaneous healthy volunteers was taken
into sodium citrate (3.8%) and transported at ambient temperature (approxi-
mately 20°C) to the laboratory. In the majority of cases, blood was taken in
the adjacent clinic, but in some cases, samples from participants and healthy
volunteers were transported over distances of up to 100 miles by courier to
Birmingham. We have demonstrated previously that the results in platelet-
rich plasma (PRP) from samples that have been transported in this way are
indistinguishable from those from locally collected samples provided that
the PRP is prepared at the site of testing.9
PRP was prepared by centrifugation at 200g for 10 minutes in a spinout
rotor. Platelet aggregation and ATP secretion were measured in PRP using a
dual Chrono-log lumi-aggregometer (model 460 VS). Autologous platelet-
poor plasma was used to set the aggregation scale before each study
according to the manufacturer’s instructions. All experimentation was
performed within 6 hours of preparation of the PRP, as described
previously.9 Priority was given to time-sensitive agonists such as ADP and
adrenaline, which were always used first and within 4 hours of blood
collection.9,11 No adjustment was made to the platelet count because there
was no significant difference in the aggregation curves to platelet agonists
within the normal range of platelet count as shown by comparison of the
response with 3 platelet agonists in healthy volunteers at the 2 extreme ends
of the normal range (supplemental Figure 1, available on the Blood Web
site; see the Supplemental Materials link at the top of the online article).
This is consistent with previous results.12-15
Platelets from the participants and healthy volunteers were routinely
exposed to ADP (3, 10, 30, and 100M), adrenaline (10, 30, and 100M),
collagen (0.3, 1, and 3 g/mL), CRP (1, 3, and 10 g/mL), PAR-1 (10, 30,
and 100M), and PAR-4 (100, 250, and 500M) peptides, arachidonic acid
(0.5, 1, and 1.5mM), U46619 (1 and 3mM), and ristocetin (1, 1.25, 1.5, and
2 mg/mL). The responses to ADP and arachidonic acid were the first to be
investigated because these are the major 2 feedback agonists and a
significant number of participants were found to have defects in Gi
signaling or in the TxA2 pathway.16 This information was used to guide
subsequent testing, notably in cases where the platelet volume was limiting.
P2RY12 analysis
The P2RY12 coding sequence was amplified from genomic DNA and
sequenced directly, as described previously.17
Data analysis
Aggregation responses at each agonist concentration were classified as
abnormal by reference to a bank of local healthy volunteers.9 ATP secretion
was calculated by the addition of a known concentration of ATP (4nM) and
normalized to a platelet count of 1  108 platelets/mL (supplemental Figure
2). Results are shown as means  SD. Statistical analysis was performed
using a 1-tailed Student t test and Cohen  statistics.
Results
The 111 index cases were composed of 81 female and 30 male
patients. There were 70 healthy volunteers. The mean age and SD
of the participants with a clinically diagnosed PFD was 41 16 years
and 31  19 years for female and male participants, respectively.
A full distribution of the ages of participants is shown in
supplemental Figure 3.
LTA and ATP secretion were determined for 9 platelet agonists
(up to 3 concentrations) on each participant alongside a control (see
“Methods”). The response of each participant was evaluated by a
minimum of 2 experts in platelet function testing and compared
with the control on the day and to a reference range that originally
consisted of 20 controls, but which had built up to 70 controls by
the end of the study. A retrospective analysis was performed to
verify the original diagnoses and a small number of adjustments
were made. This approach revealed that 64 of 111 (58%) partici-
pants (43 female and 21 male) had a clear defect in platelet
aggregation or ATP secretion to several concentrations of platelet
agonists.
Major subgroups of PFDs
Comparing the pattern of response in the 64 participants with an
identified defect in LTA or ATP secretion revealed that 54 of
64 (84%) could be assigned to 3 major diagnostic groups: those
with defects in (1) Gi signaling, (2) the TxA2 pathway, and
(3) granule secretion. The distribution of defects is in shown in
Table 1 and the characteristic features of each subgroup are
described in the following sections.
Gi-like defect. A total of 21 (32.8%) of the 64 index cases were
diagnosed with a Gi-like defect. This subgroup exhibited a defect in
aggregation and secretion to the 2 Gi-coupled heterotrimeric
receptors agonists ADP and adrenaline. A key diagnostic feature
was a transient aggregation to ADP (10M), a reduced or absent
primary wave with no secondary wave of aggregation to adrena-
line, and the absence of ATP secretion to both agonists. Similar
numbers of participants had a reduced primary wave or absent
primary response to adrenaline.16 In comparison, high concentra-
tions of ADP and adrenaline induced sustained aggregation in the
70 healthy volunteers. Representative traces to ADP and adrenaline
are shown in Figure 1.
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Reduced aggregation and secretion to low and intermediate
concentrations of other platelet agonists, most notably collagen,
was also observed in this group, which is consistent with impair-
ment of the known feedback role of ADP. At higher agonist
concentrations, sustained aggregation and a normal level of ATP
secretion was usually seen. A robust response to 1mM arachidonic
acid (Figure 1) helps to distinguish this group of participants from
those with a defect in the TxA2 pathway, as described in the next
section.
TxA2 pathway defect. A total of 14 (21.9%) of the 64 index
cases were diagnosed with a TxA2 pathway defect. This was
characterized by a marked and selective defect in aggregation and
secretion to arachidonic acid (1mM) as illustrated by the represen-
tative trace in Figure 2. In 3 of the 14 participants with this defect, a
reduced response to the TxA2-mimetic U46619 was also seen,
indicating a defect at the level of the TxA2 receptor or its
downstream signaling cascade. A normal aggregation response to
U46619 is evidence for a defect in conversion of arachidonic acid
to TxA2 because the response to U46619 is insensitive to cyclooxy-
genase blockade.9,18 Aggregation and secretion to low concentra-
tions of other platelet agonists was also reduced in this group,
which is consistent with the positive feedback role of TxA2. For
most agonists, full recovery was seen at higher concentrations (not
shown), with the exceptions of ADP and adrenaline which exhib-
ited a slowly decaying aggregation response and severely reduced
or absent secondary wave, respectively (Figure 2).
Dense granule–secretion defect. A total of 19 (30%) of the
64 index cases were diagnosed with a dense granule secretion
defect that could be due to a defect in either storage or secretion.
The level of secretion was dependent on the platelet count, which
was normalized to the observed response to PAR-1 (Figure 3A) or
PAR-4 peptides (see “Methods”). Participants were considered to
have a significant defect in secretion when the response fell outside
of the normal range determined in controls. A decrease in ATP
secretion was observed in response to all agonists, even though
several, including PAR-1, PAR-4, and CRP, induced maximal,
sustained aggregation at high concentrations. However, there was a
reduction in aggregation to low concentrations of most platelet
agonists, which is consistent with impairment of the feedback role
of ADP and TxA2. The response to a low concentration of collagen
was markedly impaired, as illustrated in the representative trace in
Figure 3A. One agonist that showed a minimal change in its
dose-response curves for aggregation was ADP, which is consistent
with our previous conclusion that secretion plays a minimal role in
aggregation to the nucleotide.9
The PAR-1 peptide (100M) elicited a limited degree of
secretion of ATP in all index cases diagnosed with a secretion
disorder (Figure 3B), with the exception of the index case (and also
other related family members) with an HPS-8 mutation (homozy-
gous).19 Secretion to the PAR-1 peptide (100M) in participants
diagnosed with a Gi or TxA2 pathway defect, as well as one
participant with a homozygous P2Y12 receptor mutation (see
below) and 2 with a heterozygote TxA2 receptor defect (see below
and refer to Mumford et al18) fell within the normal range (Figure
3B). These results demonstrate that the majority of participants
Figure 1. Aggregation to ADP and adrenaline in 2 participants diagnosed with a Gi-like defect. Aggregation in 2 participants (p) diagnosed with a Gi-like defect is shown.
The participant in panel A shows a partial primary wave response to adrenaline, whereas for a second participant shown in panel B, the primary wave is absent. “c” indicates the
control (healthy volunteer). Note that the biphasic aggregation to ADP shown in panel B would eventually decline. The patterns of aggregation are representative of other
participants diagnosed with a Gi-like defect.
Table 1. Classification of participants with mild platelet-based
bleeding defects
Type of platelet defect No. of participants % of participants
Membrane Gi signaling 21 32.8%
TxA2 pathway 14 21.9%
GPVI 4 6.2%
Gq 1 1.6%
Dense granule 19 29.7%
Complex 5 7.8%
Total 64 100%
Participants who exhibited a defect in platelet function were subdivided on the
basis of their major platelet phenotype, as described in the text.
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diagnosed with a secretion disorder elicit a limited degree of dense
granule secretion and that the maximal level of secretion to a high
concentration of a PAR-1 peptide is unaffected by mutations in the
P2Y12 ADP or TxA2 receptors.
Other, less common subgroups of PFDs
Comparison of LTA and ATP secretion results in the remaining
10 of 64 (16%) participants, along with additional tests, revealed
several further subgroups shown in Table 1, namely defects in the
GPVI signaling pathway, Gq receptor signaling, and in the ADP
and TxA2 receptors (confirmed by gene sequencing). In 2 other
participants, the pattern of defects could not be assigned to any of
these groups and is described as complex to indicate the presence
of defects in multiple pathways. These subgroups are described in
the following sections.
P2Y12 ADP receptor mutation. The index case was a 31-year-
old Asian woman with a lifelong history of severe bruising and
prolonged bleeding from cuts, who had required a blood transfu-
sion following a cesarean section. Her parents were first cous-
ins, although neither had a history of bleeding. Her brother also
had a lifelong history of prolonged bleeding from cuts but was
not available for investigation. Her full blood count and basal
coagulation tests were within the normal range. The partici-
pant’s platelets exhibited a weak, transient aggregation and
absence of secretion in response to a high concentration of ADP
(100M) that was preceded by shape change (Figure 4A). The
response was not altered in the presence of the P2Y12 receptor
antagonist AR-C67085, whereas the addition of the antagonist
reduced the response to ADP in the corresponding healthy
volunteer (Figure 4A). The participant’s platelets exhibited a
biphasic aggregation to adrenaline and a mild defect in aggrega-
tion to low concentrations of other platelet agonists, most
notably collagen (consistent with the feedback role of ADP in
supporting activation), which normalized at higher concentra-
tions (Figure 4A). The level of ATP secretion by maximal
concentrations of the PAR-1 peptide was within the normal
range, indicating that the participant did not have a secretion
defect (Figure 4B). ADP had no effect on cAMP formation by
PGE1, whereas adrenaline induced a marked decrease in the
second messenger (supplemental Figure 4).
Figure 2. Aggregation in a participant diagnosed with a TxA2 pathway defect. Aggregation in a participant (p) diagnosed with a TxA2 pathway defect. The TxA2 pathway
defect also results in the abolition of response to arachidonic acid (1mM) and impairment in response to other agonists, including ADP and adrenaline, but not to U46619,
indicating a defect in arachidonic acid metabolism. “c” indicates control (healthy volunteer). The pattern of aggregation is representative of other participants diagnosed with a
defect in arachidonic metabolism.
Figure 3. Aggregation and ATP secretion in a participant diagnosed with a dense granule defect. (A) Aggregation in a participant diagnosed with a defect in dense
granule secretion on the basis of a significantly reduced level of secretion to high concentrations of PAR-1–specific peptide and other platelet agonists, including
PAR-4–specific peptide and CRP relative to a panel of controls. “c” indicates control (healthy volunteer). The pattern of aggregation is representative of other participants
diagnosed with a secretion disorder. (B) ATP secretion was measured alongside aggregation in a Born lumi-aggregometer in PRP using Chrono-Lume reagent for the detection
of ATP. The degree of ATP secretion (after normalization to platelet count, supplemental Figure 2) to PAR-1–specific peptide (100M) in healthy volunteers and participants
diagnosed with defective dense granule secretion is shown. Participants identified with mutations in the P2Y12 (present study), TxA2 receptors,10 and HPS-819 are identified by
square brackets.
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This profile is indicative of a defect in the P2Y12 ADP receptor.
In confirmation of this, genomic DNA sequencing revealed that the
participant was homozygous for a single base deletion at nucleotide
position 36 of the P2RY12 gene. This mutation is predicted to cause
a frameshift leading to introduction of a premature stop codon
(c.36delG, p.Gly12fs), resulting in a failure to express the P2Y12
receptor.
TxA2 receptor mutations. We have recently described a
participant with a function-disrupting heterozygous mutation in the
TxA2 receptor.18 The defining features of this participant were a
marked defect in aggregation and secretion to low concentrations
of arachidonic acid and U46619. We have since identified a second
participant who is heterozygous for a distinct mutation in the TxA2
receptor, which alters receptor trafficking (Nisar and Mundell,
unpublished data, January 2012). In both participants, the defect in
aggregation and secretion is similar to that in participants with
defective arachidonic acid metabolism described above, with the
significant difference being the reduction in response to U46619.
GPVI pathway defect. We have identified 4 index patients
with a GPVI-like defect on the basis of a selective reduction in
aggregation and secretion to the GPVI-specific agonist CRP,
whereas the response to ADP, arachidonic acid, and the PAR-1–
and PAR-4–specific peptides were within the normal range (Figure
5 and data not shown). Aggregation and secretion to low concentra-
Figure 4. Aggregation and secretion in a participant with a homozygous P2Y12 mutation that prevents receptor expression. Aggregation and secretion in a participant
(p) with a homozygous mutation in P2Y12 that introduces a frame-shift mutation early in the coding sequence (c.36delG, p.Gly12fs). Responses are shown alongside a control
(c). The PRP platelet count in the control and participant were 4.1  108/mL and 3.9  108/mL, respectively.
Figure 5. Aggregation and secretion in a participant with a GPVI-like defect. Aggregation in a participant (p) diagnosed with a GPVI-like defect on the basis of a reduced
response to CRP and to rhodocytin. A similar pattern of aggregation was observed in other participants diagnosed with a GPVI-like defect. “c” indicates control.
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tions of collagen were also reduced, although recovery was seen at
higher concentrations, as illustrated by the representative traces in
Figure 5. The weaker effect on collagen relative to CRP can be
accounted for by the presence of a second collagen receptor on the
platelet surface, integrin 21, and by the marked dependency of
the response of collagen on the feedback actions of ADP and TxA2.
The snake venom toxin rhodocytin activates platelets through the
C-type lectin receptor CLEC-2, which signals through a signaling
cascade this is closely related to that of GPVI.20 The demonstration
of an impairment in aggregation to rhodocytin, as illustrated in
Figure 5, is indicative of a signaling defect downstream of GPVI
or CLEC-2.
Gq-like defect. One male index case and his sister from a
nonconsanguineous relationship were observed to have a partial
defect in aggregation and secretion to intermediate concentrations
of agonists that signal through the heterotrimeric G proteins Gq and
G13, namely PAR-1– and PAR-4–specific peptides and the TxA2
analog U46619 (supplemental Figure 5). In contrast, the responses
to ADP and CRP were only marginally inhibited, arguing against a
general defect in platelet activation. This is further supported by the
similar nature of the response to the phorbol ester PMA in the
participant’s platelets (supplemental Figure 5). Therefore, the
defect is putatively at the level of Gq or G13 or their downstream
signaling proteins.
Streamlined agonist panel testing
We next considered whether a reduced panel of LTA and ATP
secretion tests would be sufficient to enable reliable diagnosis of
PFD. After review of the above results, we developed a streamlined
panel of agonists and concentrations based on their ability to
diagnose and discriminate the above subgroups of PFDs (Table 2).
We then undertook a comparison of the diagnosis of a PFD using
this streamlined panel with the original agonist panel. These studies
took into account the extent and time course of aggregation (noting
whether it was transient or delayed) and the level of secretion of
ATP, because the extent of maximal aggregation alone does not
distinguish between the major 3 platelet function defect groups
from controls (Figure 6).
Two independent experts were blinded to previous diagnoses
and reviewed data that would have been created using the
streamlined agonist panel in 94 cases that were suitable for full
analysis. Interobserver variation was minimal, with an agreement
of approximately 90% ( statistic 0.829, P  .001). A mutually
acceptable consensus was subsequently reached for the 10% of
patients with a difference of opinion. The diagnoses from this
process were then compared with the previous historical diagnoses
using the expanded agonist list (Table 3). There was a significant
level of agreement with a  statistic of 0.721 (P  .001). In
addition, the sensitivity (87%), specificity (86%), negative predic-
tive value (84%), and positive predictive value (88%) provided
further verification of the streamlined agonist panel (Table 3).
Discussion
The most widely used test for platelet function is LTA, which
monitors the increase in light transmission through a suspension of
platelets as aggregation proceeds. Among the advantages of this
test are its relative simplicity, the ability to monitor responses to
individual agonists over time, and (in our experience) its reproduc-
ibility at the level of each donor. Furthermore, it can be combined
with real-time monitoring of ATP secretion in a lumi-aggregometer
by the addition of the luciferin-luciferase reagent. The drawbacks
of this method include the time taken to perform the assays and the
fact that many investigators consider it to be operator dependent
and to give inconsistent results. The interpretation of aggregation
traces is also complex because of the feedback effects of redundant
platelet activation pathways, although this applies to all tests of
platelet function. Several of these limitations can be minimized by
standardization of the aggregation and secretion assays, as per-
formed in this study. A similar standardization of LTA was also
used in a recent study of 229 participants to detect participants with
platelet dysfunction.8
Defining the platelet phenotype through the analysis of aggrega-
tion and secretion to 9 platelet agonists, alongside other functional
tests, provides important information on the defective pathway(s),
and in some cases the defective protein, allowing targeted genetic
analysis. It is not practical for hospital laboratories to follow this
procedure because of the time taken for the analysis and the
relatively low numbers of participants that are referred to each
center. Nevertheless, a limited analysis of platelet aggregation
using 1 or 2 concentrations of the “standard” platelet agonists
Table 2. Streamlined panel of agonists with interpretative notes for diagnosing platelet function defects
Agonist Concentration
% of maximal
aggregation,
mean SD Expected Abnormal pattern and further testing
ADP* 10M 59.8%  12.5% Maximal, sustained aggregation and
secretion
Reduced or transient aggregation and absent
secretion: use 30M
Adrenaline* 10M 70.3%  13.7% Biphasic aggregation with secretion
coincident with second phase
Reduced or absent primary wave and absent
secretion: use 30M
Arachidonic acid 1mM 71.0%  8.5% Maximal, sustained aggregation and
secretion
Absent or delayed/reduced aggregation and
secretion: use U46619 (3M)
PAR-1 receptor–specific
peptide (SFLLRN)
100M 73.8%  11.1% Maximal, sustained aggregation and
marked secretion
Transient aggregation and reduced secretion:
use PAR-4 receptor–specific peptide
(AYPGKF; 500M).
Collagen* 1 g/mL 50.4%  22.5% Sustained aggregation and secretion Reversible aggregation and absent secretion:
use 3 g/mL and collagen-related peptide
(CRP; 3 g/mL) or convulxin
Ristocetin 1.5 mg/mL 70.8%  16.1% Maximal sustained aggregation (often
biphasic) and secretion
Reduced or absent aggregation and
secretion
Different concentrations of agonists with the percentage of maximal aggregation  SD are shown.
*ATP secretion from dense granules should be measured for the following agonist concentrations: ADP (30M), adrenaline (30M), arachidonic acid (1mM),
PAR-1–specific peptide (100M), and collagen (3 g/mL).
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(ADP, adrenaline, arachidonic acid, collagen, and ristocetin) is
extremely valuable in aiding diagnosis.8
In the present study, we have validated the use of a streamlined
panel of 6 platelet agonists (Table 3) by comparing the diagnoses
made with the extended agonist panel. This streamlined agonist
panel could be used in nearly all clinical testing centers and would
serve to guide further subtyping of the PFD by a specialist
laboratory or a clinical research study through functional investiga-
tions and targeted genotyping or analysis of whole-exome sequenc-
ing data. The functional tests could include an expanded range of
platelet agonists and more specialized tests, such as measurement
of second messengers (cAMP and Ca2	 elevation), TxA2 forma-
tion, shear-based assays of platelet adhesion and aggregation, and
flow cytometric measurements of -granule secretion and glycopro-
tein receptor levels. The streamlined agonist list would also
identify nearly all of the 40% of patients in whom such tests would
appear to have limited value.
The majority of participants with an identified defect in platelet
function (approximately 80%) were assigned to 1 of 3 groups
characterized by defects in Gi signaling, TxA2 formation, and
dense granule secretion, which emphasizes the importance of these
3 pathways in supporting platelet activation during hemostasis. In
the majority of these cases, the causative gene mutation(s) is not
known and the value of the subgrouping is to enable further
functional studies and targeted gene sequencing/gene interrogation.
The relatively small number of participants with defects in the
Gq pathway is perhaps surprising given the importance of this
pathway in platelet activation. However, it may reflect the fact that
several platelet receptors signal through Gq-mediated pathways,
namely the PAR-1, PAR-4, P2Y12, and TxA2 receptors, thereby
reducing the impact of a partial defect. Alternatively, a mutation in
this pathway could cause a more severe phenotype in other tissues
that could be lethal in utero. The small number of participants with
defects in the GPVI pathway is consistent with the relatively mild
nature of bleeding associated with defects in the collagen receptor.21
There are several possible explanations for the failure to
identify a defect in platelet function in almost 40% of participants
suspected of having a platelet disorder. These include the likely
possibility that they do not have a defect in platelet activation
pathways, but rather an abnormality in another component of the
hemostatic response, such as increased fibrinolysis or an impair-
ment of vascular integrity. Alternatively, it is possible that they
have a defect that has not been detected in the platelet function tests
that have been performed, such as an enhanced activity of an
inhibitory pathway. The limited repertoire of platelet function tests
used in the present study may also have contributed to the failure to
diagnose a platelet defect. However, in work that is not reported in
this study, we have performed additional platelet tests in many of
the participants who have been investigated in this study, including
measurement of platelet aggregation on collagen at intermediate
Figure 6. Maximal aggregation response in participants with platelet function defects and healthy volunteers. The percentage of maximal aggregation was measured
in a Born lumi-aggregometer in PRP in response to the shown concentrations of the following agonists: ADP, adrenaline, arachidonic acid, collagen, PAR-1–specific peptide,
and ristocetin. The results are shown as the percentage increase in light transmission relative to platelet-poor plasma.
Table 3. Comparison of the expanded agonist panel and a streamlined agonist panel in diagnosing platelet function defect
Expanded agonist panel positive Expanded agonist panel negative
Streamlined agonist panel positive 45 6 Positive predictive value 88%
Streamlined agonist panel negative 7 36 Negative predictive value 84%
Sensitivity ( 87% ) Specificity ( 86% )
Table shows a comparison between diagnoses of platelet function defect using the expanded agonist panel and a streamlined agonist panel. The sensitivity (87%),
specificity (86%), negative predictive value (84%), and positive predictive value (88%) are shown. The kappa statistic was 0.721 (P  .001).
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rate of shear (1000/s), and investigation of the inhibitory action of
prostacyclin and sodium nitroprusside, which elevate cAMP and
cGMP, respectively, and clot retraction. No defect was observed in
any of these responses in patients for whom aggregation and
secretion fell within the normal range.
The phenotyping of platelets has been used to direct genotyping
and has led to the identification of participants with a homozygous
defect in the P2Y12 ADP receptor gene (present study) and
2 heterozygous mutations in the TxA2 receptor, one of which has
been described previously.18 The homozygous P2Y12 ADP receptor
gene mutation reported in the present study is the 10th mutation to
be reported in the nucleotide receptor.10 A third heterozygous
mutation in the TxA2 receptor has also been reported recently.22
The only other reported mutation in the TxA2 receptor, Arg60Leu,23
may be a rare single nucleotide polymorphism because there is no
clear defect in function of the receptor in cell line studies.24,25 We
have not identified participants with mutations in the PAR-1 and
PAR-4 thrombin receptors or the collagen receptor GPVI. There are
no reported participants with mutations in the PAR-1 and PAR-4
receptors, possibly because they are incompatible with life, and
only 2 patients with mutations in GPVI have been reported.26,27 The
small number of participants with mutations in platelet surface
receptors suggests that receptor mutations account form a
relatively small proportion of mutations that give rise to
bleeding symptoms, with the majority being in intracellular
signaling pathways or functional processes such as secretion or
TxA2 formation. Identifying the mutations that give rise to these
function disorders requires a more high-throughput approach such
as that offered by whole-exome sequencing or a targeted second-
generation sequencing array.28
The present study represents a comprehensive investigation of
participants with a clinically suspected platelet disorder alongside
healthy volunteers. The participants have been grouped on the basis
of the identified disorder, with the majority having defects in one of
the major feedback pathways of platelet activation: Gi signaling,
the TxA2 pathway, and dense granule secretion. A few of these
participants have defects at the level of the ADP and TxA2 receptor,
but the majority have mutations downstream of receptor activation,
necessitating the use of second-generation sequencing and targeted
interrogation based on the functional results to establish the
causative mutation(s). Based on the present results, we developed a
streamlined platelet agonist list that could be performed in most
clinical testing centers and a sequence of interpretation (Table 3).
This interpretation takes into account the pattern, but not the
magnitude, of the defect in aggregation and whether secretion is
also defective.
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